22-brain-chemistry

Valuation

Generous asset valuation: $40,000,000,000. The listed price is the platform maximum; acquisition at valuation is handled by direct enquiry.

NeuroElement™ — Multi-Target Brain Optimization Formulation

NeuroElement™ — Multi-Target Brain Optimization Formulation

Master index of all projects: PROJECTS_INDEX.

Last edited: 2026-05-02

Status: Patent-Pending Product, Pre-Launch

Date: March 3, 2026 (priority date)

Contact: crioneaka@outlook.com

USPTO Patent Status

> NeuroElement is the subject of US patent application 19/555,525 with 24 claims, filed March 3, 2026 (USPTO Confirmation No. 9226). The application has been filed with the USPTO and is pending examination. It is not a granted patent. For the canonical portfolio, see ../PATENT_PORTFOLIO.md. For the official USPTO filing receipt (Form N-417) inventory, see ../N417_FILING_RECEIPTS.md.

SAFETY DISCLAIMER

This product is patent-pending and has not been evaluated by the FDA. Statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified health professional before using any supplement, especially if you are pregnant, nursing, taking medication, or have a medical condition.

What NeuroElement Is

A computationally-designed 7-compound brain optimization formulation, developed across approximately 20 years of research and finalized using a proprietary algorithmic method that analyzed:

• 54 diseases and the brain-chemistry mechanisms underlying each
• 65 neurotransmitters and their precursor / metabolic pathways
• 40 neurobiochemical mechanisms governing brain function and degeneration

The 7 compounds are selected to:

• Deliver 10 of 14 brain-essential chemical elements that conventional supplements miss or under-deliver
• Cross the blood-brain barrier in bioavailable form
• Cover an estimated 85% of mechanism space and 89% of disease space in published brain-supplement literature

Detailed claim coverage and the 24-claim breakdown are in the patent application; the design rationale and compound rationale are in the product valuation document below.

Documentation

• PRODUCT_VALUATION.md — full market analysis (TAM/SAM/SOM, comparables, projected revenue), formulation rationale, IP positioning
• BRAIN_RESEARCH_INDEX.md — index into the 20-year research record
• neuroelement-brain-supplement.html — public-facing product page
• neuroelement-description-cms.html — store CMS / catalog description
• MJFF_PROPOSAL_LETTER.txt — outreach letter to the Michael J. Fox Foundation
• google_patents_search_list.txt — companion prior-art search results
• patent_application/ — patent application source materials
• brain_research/, research_docs/, data/ — research substrate
• brain_research_tool.py — design / analysis tool
• tests/ — validation tests

Project Structure

Use Cases

• Direct-to-consumer brain-health supplement (FDA dietary supplement pathway)
• Licensing to existing supplement brands for formulation incorporation
• Research collaboration with neurodegenerative-disease foundations (MJFF letter on file)
• IP-only sale or assignment of application 19/555,525 family

Contact

Christopher Gabriel Brown

1341 Wellington Cove, Lawrenceville, GA 30043-5255, USA

Email:: crioneaka@outlook.com

Email: crioneaka@outlook.com

Brain Chemistry Research Reference Database

Brain Chemistry Research Reference Database

Master Index

Author: Christopher Gabriel Brown

Generated: 2026-03-12

Version: 1.0.0

System Overview

A research reference database for exploring brain chemistry, neurotransmitters,

and elemental compound relationships with disease mechanisms. Cross-references

compounds with diseases based on shared elemental mechanisms.

Built on the Alchemy Data V2 foundation system.

Note: Mechanism overlap between compounds and diseases indicates shared

biochemical elements, not demonstrated therapeutic efficacy. No clinical trials

have been conducted on these compound-disease associations.

Database Statistics

Connected Projects

Research Documentation

Quick Start

# Import the brain research system
from brain_research.brain_chemistry_db import BrainChemistryDB
from brain_research.brain_compound_analyzer import BrainCompoundAnalyzer
from brain_research.neurotransmitter_db import NeurotransmitterDB

# Initialize
db = BrainChemistryDB()
analyzer = BrainCompoundAnalyzer()
nt_db = NeurotransmitterDB()

# Get system stats
stats = db.get_stats()

# Search across all databases
results = db.search_all("dopamine")

# Compare two compounds
comparison = analyzer.compare_compounds("C-H-O-N-Zn", "C-H-O-N-Cu")

# Analyze compound for specific disease
analysis = analyzer.analyze_for_disease("C-H-O-N-Zn", "Parkinson's")

# Get neurotransmitter info
dopamine = nt_db.get_by_name("dopamine")

# Get full disease profile
profile = db.get_disease_full_profile("Alzheimer's")

CLI Tool

python brain_research_tool.py --stats
python brain_research_tool.py --search "dopamine"
python brain_research_tool.py --compare "C-H-O-N-Zn" "C-H-O-N-Cu"
python brain_research_tool.py --disease "Alzheimer's"
python brain_research_tool.py --element "Zn"
python brain_research_tool.py --neurotransmitter "serotonin"
python brain_research_tool.py --diagnose --symptoms "tremor,shuffling gait"
python brain_research_tool.py --cross-disease
python brain_research_tool.py --timeline
python brain_research_tool.py --timeline pain
python brain_research_tool.py --medicine "sumatriptan"
python brain_research_tool.py --fastest
python brain_research_tool.py --report

NO INTELLECTUAL PROPERTY TRANSFER

All rights remain with Christopher Gabriel Brown.

Research information only. Commercial use requires licensing.

22 - Brain Chemistry

22 - Brain Chemistry

> Internal playbook -- not for public eyes.

> Last scaffolded: 2026-05-11

1. Identity

2. One-liner

> | Field | Value | |---|---| | Application No. | 19/555,525 | | Type | Utility (non-provisional) | | Filing Date | March 3, 2026 | | Confirmation No. | 9226 | | Claims | 24 — covering composition of matter, computational design method, formulation process, and method of treatment | | Subject Matter | NeuroElement...

*(Edit this once. It becomes the single sentence you reuse in replies,

on the catalog page, and at the top of any future write-up.)*

3. What's actually in the folder

• .claude/ (1 entries)
• .pytest_cache/ (4 entries)
• brain_research/ (12 entries)
• data/ (9 entries)
• NeuroElement-Brain-Chemistry-Research/ (18 entries)
• patent_application/ (16 entries)
• product/ (1 entries)
• research_docs/ (7 entries)
• sales-pitches/ (3 entries)
• tests/ (6 entries)
• 1 light trigger.txt
• BRAIN_RESEARCH_INDEX.md
• CHANGELOG.md
• Contact Information.txt
• CONTACT_INFO.txt
• google_patents_search_list.txt
• hybrid-svg-generator.html
• MANIFEST.json
• MJFF_PROPOSAL_LETTER.txt
• neuroelement-brain-supplement.html
• neuroelement-description-cms.html
• PLAYBOOK.md
• PRODUCT_VALUATION.md
• README.md
• requirements.txt
• ...+more

4. README at a glance

Top sections found in README.md:

• USPTO Patent Status
• SAFETY DISCLAIMER
• What NeuroElement Is
• Documentation
• Project Structure
• Use Cases
• Contact

(Full text: D:\special\22-brain-chemistry\README.md)

5. Hook lines (pick the one that fits the reader)

• (default) | Field | Value | |---|---| | Application No. | 19/555,525 | | Type | Utility (non-provisional) | | Filing Date | March 3, 2026 | | Confirmation No. | 9226 | | Claims | 24 — covering composition of matter, computational design method, formulation process, and method of treatment | | Subject Matter | NeuroElement...
• (skeptic / 'what is this really?') TODO -- one honest sentence about

what's solved here that wasn't before.

• (buyer's-finance angle) TODO -- pricing/risk framing (zero-upfront,

4-step credit-forward, revenue share if applicable).

• (competitor question) TODO -- the one comparable product or approach

this most often gets confused with, and the one-sentence delta.

6. Reply patterns

When inbound lands, fall back to the cross-portfolio patterns in

D:\special\manager\emails\PLAYBOOK_software_for_data.md (sections 5

and 8 are reusable across every project) and adapt the specifics.

The product-specific bits to fill in here (TODO):

• One objection unique to this project + the honest answer
• One pricing anchor unique to this project
• One reason to walk away that's worth saying out loud

7. Status & gaps

• Vault: EMPTY -- no archive (must create before 'Send Vault' works)
• Catalog presence: TODO -- search cri-one.com/store for this product

and paste the live URL here.

• PoF readiness: TODO -- is there a working demo / sample / proof a

prospect could run in under an hour?

• NDA-gated technical brief: TODO -- written? not written? where?
• Critical missing piece before this can close: TODO.

8. Quick links

• Folder: D:\special\22-brain-chemistry\
• Catalog (cri-one.com): TODO
• Related projects in portfolio: TODO (cross-reference here once mapped)

*This scaffold was auto-generated. Replace TODOs as you learn each project

better. Search across all playbooks: grep -ri "<term>" D:\special\\PLAYBOOK.md

Product Valuation Report

Product Valuation Report

NeuroElement™ — Multi-Target Brain Optimization Formulation

U.S. Patent Application No. 19/555,525 | Filed March 3, 2026

EXECUTIVE SUMMARY

Product: A patent-pending, computationally-designed 7-compound brain optimization formulation that delivers 10 of 14 brain-essential chemical elements through bioavailable, blood-brain-barrier-crossing forms. Designed using a proprietary algorithmic method analyzing 54 diseases, 65 neurotransmitters, and 40 neurobiochemical mechanisms.

Inventor: Christopher Gabriel Brown

IP Status: Nonprovisional Utility Patent Application 19/555,525 (filed 03/03/2026)

Priority Date: March 3, 2026

Research Duration: ~20 years

1. MARKET ANALYSIS

1.1 Total Addressable Market (TAM)

1.2 Serviceable Addressable Market (SAM)

The premium/ultra-premium brain supplement segment (products priced >$60/month) represents approximately 25-30% of the U.S. market:

SAM (U.S., 2026): ~$1.0B - $1.2B

1.3 Serviceable Obtainable Market (SOM)

Conservative Year 1-3 capture with DTC launch:

• Year 1: 0.05% = $500K - $600K
• Year 2: 0.15% = $1.5M - $1.8M
• Year 3: 0.50% = $5.0M - $6.0M

2. COMPETITIVE LANDSCAPE & PRICING

2.1 Competitor Pricing Matrix

2.2 Competitive Advantages

No competitor approaches this product on scientific rigor, breadth of coverage, or IP protection.

3. RECOMMENDED PRICING

3.1 Pricing Strategy

3.2 Unit Economics (DTC Model)

3.3 Revenue Projections

4. INTELLECTUAL PROPERTY VALUATION

4.1 IP Assets

4.2 Patent Valuation Methods

Method 1: Cost Approach (Research Investment)

• 20 years of research and development
• Thousands of dollars in direct costs
• Opportunity cost of researcher time
• Estimated replacement cost: $2M - $5M

Method 2: Market Approach (Comparable Transactions)

• Onnit/Alpha Brain acquired by Unilever: ~$250-400M (no patent)
• Prevagen patent (single ingredient): company valued at $100M+
• Thesis Nootropics: $13.5M raised pre-revenue
• IP-only comparable: $5M - $20M

Method 3: Income Approach (DCF on Patent Life)

• Patent life: 20 years from filing (through ~2046)
• Projected Year 5 revenue: $17.8M
• Gross margin: 80%
• Discount rate: 25% (early-stage)
• Terminal value at patent expiration: $0
• NPV of patent rights: $15M - $50M

4.3 IP Valuation Summary

5. TOTAL PRODUCT / COMPANY VALUATION

5.1 Pre-Revenue (Current State)

5.2 At Revenue Milestones

5.3 Strategic Acquisition Scenarios

6. COMPARABLE TRANSACTIONS

7. RECOMMENDED LISTING PRICE

For Christopher Gabriel Brown's technology portfolio at christophergabrielbrown.com:

Technology Transfer / Full IP Sale

Note: Prices above reflect risk-adjusted values. If patent is granted, prices may be revised upward.

DTC Product Sale (Keep IP, Sell Product)

8. RISK FACTORS

8.1 IP / Patent Risks (HIGH)

1. Patent not yet granted: Application 19/555,525 is pending. USPTO examination may result in rejections, narrowed claims, or denial. Average utility patent allowance rate is ~52%. A pending application provides no enforceable IP rights.

2. Prior art exposure: Individual compounds (Mg-threonate, NAC, citicoline, etc.) are well-known and sold as supplements. Claims may be limited to the specific 7-compound combination and dosing schedule.

3. Enforcement cost: Even if granted, patent litigation costs $2-5M per defendant. Small supplement companies routinely design around composition patents.

8.2 Regulatory Risks (HIGH)

4. Ebselen classification: Ebselen is a synthetic compound not sold as a dietary supplement in the US. FDA may classify the product as a drug rather than a supplement, requiring an NDA/IND (cost: $50-100M, timeline: 7-12 years).

5. FDA/FTC compliance: Structure-function claims only. Any disease claims (Alzheimer's, Parkinson's, etc.) in marketing would trigger FDA enforcement. The research framing around "curing diseases" must not appear in product marketing.

6. NAC regulatory status: FDA issued warning letters in 2020 stating NAC may not qualify as a dietary supplement ingredient. Status remains uncertain.

8.3 Clinical / Scientific Risks (HIGH)

7. No clinical trial data: The formulation has never been tested in humans. Mechanism coverage percentages (85%) are computational, not validated in vivo.

8. Computational methodology limitations: The "alchemy" matching algorithm uses elemental set intersection to score compounds against diseases. This is a keyword/category matching approach, not a pharmacological model. Claiming compounds "treat" diseases based on shared elements is not supported by pharmacology.

9. No published peer review: The research has not been submitted to or published in peer-reviewed journals.

8.4 Market / Business Risks (MODERATE)

10. Pre-revenue: No sales, no customers, no brand awareness. Customer acquisition cost (CAC) in DTC supplements is $40-100/customer.

11. Competition from established brands: Qualia Mind, Alpha Brain, etc. have existing customer bases, distribution, and marketing budgets ($5-20M/year).

12. Single-product company: All revenue depends on one SKU. No pipeline diversification.

8.5 Manufacturing Risks (LOW-MODERATE)

13. Ebselen sourcing: Not widely available from supplement-grade suppliers. May require pharmaceutical chemical suppliers with higher costs.

14. Geometric dilution: Standard pharma technique but requires trained operators and validated process.

9. RISK MITIGANTS

1. 24 patent claims with fallback positions across 4 independent claim types

2. FTC-compliant positioning focusing on mechanism coverage, not disease treatment

3. Geometric dilution is standard pharma technique, scalable to contract manufacturing

4. All non-ebselen ingredients are established supplement ingredients with safety data

5. Divided dosing schedule (AM/PM) addresses real pharmacological interactions (Fe/NAC separation)

10. RISK-ADJUSTED VALUATION

The base valuation in Sections 4-5 assumes the patent is granted, ebselen is permitted as a supplement ingredient, and revenue projections are met. Applying probability-weighted risk adjustment:

Key Assumptions Behind Risk-Adjusted Value

• Patent prosecution success is assumed at 45% (vs. 52% average, due to prior art risk on individual compounds)
• Ebselen supplement viability is treated as uncertain (no FDA precedent for synthetic organoselenium as supplement)
• Revenue projections assume no clinical trial requirement
• Value of the research database and computational method is estimated at $200K-500K independent of the product

CONCLUSION

NeuroElement™ has significant upside potential based on a novel computationally-designed formulation, a pending patent application, and a large addressable market. The base (unadjusted) valuation range is $7.5M - $25M for the IP portfolio.

However, applying probability-weighted risk adjustment for patent uncertainty, ebselen regulatory risk, and pre-revenue status, the risk-adjusted value is approximately $6.3M.

Key value drivers to increase valuation:

1. Patent allowance (could add $5-10M)

2. FDA/regulatory clarity on ebselen as supplement ingredient

3. Any human clinical data (even pilot study)

4. First $1M ARR milestone (proves market demand)

Valuation prepared March 3, 2026

U.S. Patent Application 19/555,525

All rights reserved — Christopher Gabriel Brown

pytest cache directory

pytest cache directory #

This directory contains data from the pytest's cache plugin,

which provides the --lf and --ff options, as well as the cache fixture.

Do not commit this to version control.

See the docs for more information.

Patent Filing Checklist & IP Analysis

Patent Filing Checklist & IP Analysis

Inventor: Christopher Gabriel Brown

Date Prepared: March 3, 2026

Updated: March 3, 2026 - Upgraded to NONPROVISIONAL UTILITY APPLICATION

APPLICATION FILES IN THIS DIRECTORY

FILING CHECKLIST - NONPROVISIONAL UTILITY PATENT

Required Documents

• [ ] Transmittal Form (PTO/AIA/15) - See NONPROVISIONAL_UTILITY_PATENT_APPLICATION.md
• [ ] Specification in DOCX format - Paragraphs [0001]-[0068], MUST be DOCX to avoid $400 surcharge
• [ ] Claims - 24 claims (3 independent + 21 dependent) - REQUIRED for nonprovisional
• [ ] Abstract - 150 words, single paragraph, separate page
• [ ] Drawings - See PATENT_DRAWINGS_DESCRIPTIONS.md (9 sheets, including new FIG. 8 and FIG. 9)

Must be converted from text descriptions to formal black-ink drawings per 37 CFR 1.84

• [ ] Oath or Declaration - Signed by inventor (template in application file)
• [ ] Application Data Sheet (ADS) - Filled out via Patent Center online
• [ ] Micro Entity Certification - Required for reduced fees

Required Fees (Micro Entity)

• [ ] Basic Filing Fee .................... $ 80.00
• [ ] Utility Search Fee .................. $ 170.00
• [ ] Utility Examination Fee ............. $ 200.00
• [ ] Non-DOCX Surcharge .................. $ 0.00 (MUST file in DOCX!)
• [ ] TOTAL DUE AT FILING ............... $ 450.00

Before Filing

• [ ] Create USPTO.gov account at https://patentcenter.uspto.gov
• [ ] Verify identity (required for Patent Center access)
• [ ] Confirm micro entity status qualification:
• [ ] Income below threshold (3x median household income)
• [ ] Not named on more than 4 previously filed patent applications
• [ ] Not assigned/obligated to assign to entity exceeding size limits
• [ ] CRITICAL: Convert specification to DOCX format (REQUIRED since Jan 2024

to avoid $400 surcharge). Format requirements:

• Font: Times New Roman 12pt
• Line spacing: 1.5 or double-spaced
• Margins: Top 3/4", Left 1", Right 3/4", Bottom 3/4"
• Paragraph numbers in [0001] format, bold
• [ ] Convert drawing descriptions to formal patent drawings (black ink, 9 sheets)
• Margins: Top 1", Left 1", Right 5/8", Bottom 3/8"
• Sheet numbering: "1/9", "2/9", etc.
• [ ] Print and sign Oath/Declaration
• [ ] Review all 24 claims for specification support
• [ ] Verify recipe weights in paragraphs [0055]-[0057]

Filing Steps

1. Log in to USPTO Patent Center: https://patentcenter.uspto.gov

2. Select "File a new application"

3. Select "Nonprovisional Utility" application type

4. Upload specification + claims + abstract as SINGLE DOCX file

5. Upload drawings as PDF/TIFF/JPEG (9 sheets)

6. Fill out Application Data Sheet (ADS) online

7. Upload signed Oath/Declaration

8. Submit Micro Entity Certification

9. Enter domestic benefit claims (63/552,008, 18/650,137, 19/031,884, 19/177,547)

10. Pay fees ($450 micro entity total)

11. Receive application number and filing date

12. SAVE confirmation receipt

After Filing

• [ ] Record application number: _______________
• [ ] Record filing date: _______________
• [ ] Monitor Patent Center for Office Actions
• [ ] Respond to Office Actions within 3 months (extendable to 6 with fee)
• [ ] Consider PCT filing within 12 months for international protection
• [ ] Budget for Issue Fee ($300 micro entity) when approved

FEE SCHEDULE (2026) - NONPROVISIONAL UTILITY

YOUR COST: $450 to file + $300 if approved = $750 total (micro entity)

NOTE: File in DOCX format to avoid the $100 surcharge!

IP ANALYSIS

What Is Already Protected (Copyright)

Recommendation: Register copyright with U.S. Copyright Office (~$65)

for statutory damages eligibility. Register the software and databases as

a single collection if possible.

What Is Patentable (Novel)

Existing Patents to Monitor

Your Existing Patent Portfolio

CRITICAL: Review these filings to determine if any contain brain

chemistry / formulation subject matter. If so, the new provisional can

claim priority to the earliest related filing, potentially giving you

a priority date as early as February 9, 2024.

PATENT CLAIMS STRATEGY

Claim Structure

The 20 claims in the application are structured as follows:

Independent Claims (3):

• Claim 1: Composition of matter (the 7-component formulation)
• Claim 15: Method of treatment (using the composition)
• Claim 18: Computational method (for designing the composition)

Dependent Claims:

• Claims 2-8: Specific dose ranges for each component
• Claim 9: Divided dosing (AM/PM) embodiment
• Claim 10: Iron/zinc competitive absorption feature
• Claims 11-12: Mechanism and disease coverage thresholds
• Claim 13: Ebselen as lithium mimetic
• Claim 14: Pharmaceutical carrier/excipient
• Claims 16-17: Specific disease targets and treatment duration
• Claims 19-20: Computational method refinements

Why This Claim Structure Is Strong

1. Three independent claims = three separate bases for patent protection

2. Composition claim is the broadest - protects the formulation itself

3. Method of treatment protects the use even if someone reformulates

4. Computational method protects the design process (hardest to design around)

5. Dependent claims provide fallback positions if independent claims narrowed

Potential Examiner Objections & Responses

NEXT STEPS

Immediate (This Week)

1. Review this application for accuracy

2. Verify micro entity status

3. Create USPTO.gov account

4. Hire patent illustrator or convert drawings yourself

Short-Term (Within 30 Days)

5. File provisional application via Patent Center ($80)

6. Receive provisional application number

7. Register copyright for databases and software ($65)

Medium-Term (Within 12 Months)

8. Consult patent attorney about nonprovisional conversion

9. Consider PCT filing for international protection

10. Conduct additional prior art search

11. File nonprovisional application claiming priority to provisional

Long-Term (After Patent Issues)

12. Seek licensing partners for pharmaceutical development

13. Monitor for infringing products/patents

14. Pay maintenance fees at 3.5, 7.5, and 11.5 years

IMPORTANT DISCLAIMERS

1. This document was prepared with AI assistance and should be reviewed

by a registered patent attorney or agent before filing.

2. Patent claims may need refinement based on professional legal review.

3. The inventor should verify all scientific claims and dosage ranges

cited in the specification.

4. Filing a patent application does not guarantee patent issuance.

The USPTO will examine the application for novelty, non-obviousness,

and utility.

5. The Pro Se Assistance Program (https://www.uspto.gov/patents/basics/

using-legal-services/pro-se-assistance-program) provides free guidance

for inventors filing without an attorney.

NO INTELLECTUAL PROPERTY TRANSFER

All rights remain with Christopher Gabriel Brown.

This archive contains 18 documents; 12 more beyond this preview. The complete folder ships as the product.